User:Mr. Ibrahem/Tafenoquine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Tafenoquine
Clinical data
Trade namesKrintafel, Arakoda, others
Other namesEtaquine,[1] WR 238605,[1] SB-252263
AHFS/Drugs.comKrintafel Monograph
Arakoda Monograph
MedlinePlusa618050
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classAntimalarial
Legal status
Legal status
Identifiers
  • N-[2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
Chemical and physical data
FormulaC24H28F3N3O3
Molar mass463.493 g/mol
3D model (JSmol)
  • FC(F)(F)c3cc(Oc1c(OC)cc(NC(C)CCCN)c2nc(OC)cc(c12)C)ccc3
  • InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3 checkY
  • Key:LBHLFPGPEGDCJG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tafenoquine, sold under the brand name Krintafel among others, is a medication used to prevent and to treat malaria.[4] With respect acute malaria it is used together with other medications to prevent relapse by Plasmodium vivax.[4] It may be used to prevent all types of malaria.[4] It is taken by mouth.[5]

Common side effects include vomiting, headache, and dizziness.[5] Other side effects may include methemoglobinemia, trouble sleeping, and anaphylaxis.[5] In people with G6PD deficiency, red blood cell breakdown may occur.[5] Use in pregnancy is not recommended.[5] Tafenoquine is in the 8-aminoquinoline family of medications.[4] How it works is unclear but it is effective both in the liver and blood.[5][4]

Tafenoquine was approved for medical use in Australia and in the United States in 2018.[4][6] In the United States, as of 2019, a course of treatment costs about US$43.[7] Tafenoquine is related to primaquine.[8]

References[edit]

  1. ^ a b Peters W (1999). "The evolution of tafenoquine--antimalarial for a new millennium?". J R Soc Med. 92 (7): 345–352. doi:10.1177/014107689909200705. PMC 1297286. PMID 10615272.
  2. ^ a b Use During Pregnancy and Breastfeeding
  3. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 9 July 2021. Retrieved 10 September 2020.
  4. ^ a b c d e f Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID 31751320. Archived (PDF) from the original on 24 March 2021. Retrieved 23 November 2019.
  5. ^ a b c d e f "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Archived from the original on 7 August 2020. Retrieved 22 November 2019.
  6. ^ Hounkpatin, Aurore B; Kreidenweiss, Andrea; Held, Jana (March 2019). "Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data". Infection and Drug Resistance. 12: 553–570. doi:10.2147/IDR.S151031.
  7. ^ "Krintafel Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 9 July 2021. Retrieved 22 November 2019.
  8. ^ "Tafenoquine Approved for Malaria Prophylaxis and Treatment". Centers for Disease Control and Prevention (CDC). 25 April 2019. Archived from the original on 9 July 2021. Retrieved 22 November 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tafenoquine&oldid=1193077336"